Geminin and Cdt1 play an essential role in the initiation of DNA replication, by regulating the chromatin loading of the MCM complex. In this study, we showed that the transcription of human Geminin and Cdt1, as well as that of MCM7, is activated by transcription factors E2F1-4, but not by factors E2F5-7. Analysis of various Geminin and Cdt1 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the transcriptional activation. The promoter activity for human Geminin was activated by the E7, but not E6, oncogene of human papillomavirus type 16. While E2F1-induced activation of human Cdt1 gene transcription was suppressed by pRb, but not by p107 or p130, its E2F4-induced activation was suppressed by pRb, p107, and p130. Furthermore, the promoter activities of human Geminin and Cdt1 were demonstrated to be growth-dependent. Taken together, the results demonstrate that Geminin and Cdt1 constitute targets for various members of the E2F family of transcription factors, and that expression of Geminin and Cdt1 is perhaps mediated by the activation of a pRb/ E2F pathway.
Introduction
To better understand the roles of the E2F transcription factors, identification of the targets that connect E2F activation to cell cycle progression and initiation of DNA synthesis is important. Genes that are regulated by the E2F transcription factors include cell cycle regulators, such as cyclin E, cyclin A, cdc2, and cdk2 (Dalton, 1992; Furukawa et al., 1994; Ohtani et al., 1995; Schulze et al., 1995; Tommasi and Pfeifer, 1995; Botz et al., 1996; Geng et al., 1996; Huet et al., 1996) . Other E2F targets include genes important for DNA synthesis, such as DNA polymerase alpha (Pearson et al., 1991) , thymidine kinase (Ogris et al., 1993; Karlseder et al., 1996; Rotheneder et al., 1999) , and dihydrofolate reductase (DHFR) (Slansky and Farnham, 1996) . In mammals, the E2F family of transcription factors consists of seven members (E2F1-7). The majority of these (E2F1-5) have transactivation domains, and can activate the expression of target genes when bound to DNA (Dyson, 1998; Harbour and Dean, 2000) . In general, E2F1, E2F2, and E2F3 function during the G1-S progression of the cell cycle, whereas E2F4 and E2F5 function largely during quiescence and are considered to be involved mainly in repression (Dyson, 1998; Harbour & Dean, 2000) . When overexpressed, E2F1, E2F2, and E2F3 (and to a lesser extent E2F4) function as potent transcriptional activators, and each by itself is sufficient to induce the entry of quiescent cells into the S phase (Lukas et al., 1996; DeGregori et al., 1997) . On the other hand, E2F6 lacks the Cterminal transactivation domain found in the other E2F transcription factors, and has been shown to be a potent transcriptional repressor (Trimarchi and Lees, 2002) . E2F7, the most recently identified member of the E2F family of transcription factors, also has the properties of a transcriptional repressor, capable of negatively influencing cellular proliferation (De Bruin et al., 2003) . All the members, except for E2F7, possess the ability to heterodimerize with members of the DP family (DP1 and DP2) (Helin et al., 1993; Zhang and Chellappan, 1995) .
The growth-suppressive properties of retinoblastoma protein (pRb) are thought to be dependent mainly on its ability to regulate the E2F transcription factors (Dyson, 1998; Trimarchi and Lees, 2002) . pRb binds to one of the E2F transcription factors during the G1 phase of the cell cycle, and inhibits activation of the E2F-dependent target genes. Thus, pRb/E2F complexes are involved in the active repression of gene expression. In response to mitogenic signals, pRb is phosphorylated by the cellcycle-dependent kinases, cyclin D/cdk4 or cyclin D/ cdk6, and cyclin E/cdk2, and transcriptionally active E2F is released. It is believed that functional inactivation of pRb, and the consequent inappropriate release of transcriptionally active E2F, is an essential step in tumorigenesis (Sherr, 1996) .
Although direct connections between E2F and the main components of the DNA replication machinery were revealed by the discovery that the expression of Orc1 (Ohtani et al., 1996) , Cdc6 (Ohtani et al., 1998; Yan et al., 1998; Harbour and Dean, 2000) , and the multiple minichromosome maintenance (MCM) complex genes (Duronio et al., 1998; Leone et al., 1998; Ohtani et al., 1999) can be induced by E2F, the mechanism underlying the transcriptional regulation of the newly identified DNA replication initiators Geminin and Cdt1 is still not well understood. Geminin inhibits DNA replication by preventing incorporation of the MCM complex into the prereplication complex (McGarry and Kirschner, 1998) . In synchronized HeLa cells, Geminin is absent during the G1 phase, accumulates during the S, G2, and M phases, and disappears during the metaphase-anaphase transition, suggesting that it inhibits DNA replication during the S, G2, and M phases, and its destruction during the metaphaseanaphase transition permits replication in the succeeding cell cycle (McGarry and Kirschner, 1998) . Geminin interacts tightly with Cdt1, a replication initiation factor necessary for MCM loading (Wohlschlegel et al., 2000) . In the normal cell cycle, Cdt1 is present only during the G1 and S phases, whereas Geminin is present during the S, G2, and M phases, suggesting that Geminin inhibits inappropriate origin firing by targeting Cdt1. Accumulating evidence suggests that Geminin is overexpressed in certain tumors, suggesting that disturbance of the Geminin/Cdt1 balance could potentially promote tumorigenesis (Wohlschlegel et al., 2002; Hansel et al., 2003) . In the present study, we showed that the E2F-family transcription factors directly activate human Geminin and Cdt1 expression. Moreover, the human Geminin promoter can also be transactivated by the E7 oncogene of human papillomavirus (HPV) type 16. Furthermore, members of the pRb family of pocket proteins suppress the E2F-mediated transactivation of human Cdt1. Taken together, it would appear that the expression of human Geminin and Cdt1 in tumors is mediated by the activation of a pRb/E2F pathway.
Results

Characterization of the human Geminin and Cdt1 promoter to identify cis-elements
To obtain a complete overview of the promoter region of human Geminin and Cdt1, which are essential DNA replication initiators, we searched the proximal region of the transcription start site for potential cis-elements using TRANSFAC (ver. 4.0), and recognized several targets, including GC-box, E-box, and E2F-binding consensus sequences (Figure 1 ). The human Geminin promoter contained a cluster of GC-box and typical TATA box (À290/À293 and À292/À295) sequences near the transcription start site (Figure 1a ), whereas the human Cdt1 promoter contained a cluster of GC-box sequences, but no consensus TATA box near the transcription start site (Figure 1c ). We noted that two short segments located within intron 1 of human Geminin showed about 85% identity with the mouse and rat Geminin sequences (Figure 1b) . One of the evolutionally conserved regions contained an E2F-responsive sequence, 5 0 -TTTGGCGC-3 0 , at position þ 378/ þ 385 relative to the transcriptional initiation site ( þ 1), indicating the functional importance of this sequence (Figure 1b) . The E2F-responsive sequence was originally identified as 0 TTTCGCGC 0 in the adenovirus E2 promoter (Kovesdi et al., 1986) , and similar sequences were recognized in the promoters of various other genes. In the promoter region of human Cdt1, we Figure 1 Schematic representation of the human Geminin (a), Cdt1 (c), and MCM7 (d) promoter-luciferase plasmid and their derivatives. Putative transcription factor binding sites for Sp1 (GCbox; arrow), Myc (E-box; circular), E2F (small box), and the position of the TATA-box are indicated. Exons (boxes) and the translational initiator (ATG; bent arrows) and terminator (TGA) codons are indicated. Open boxes indicate Luc used for promoter activity. The positions of the promoter construct are numbered relative to the transcription initiation site at þ 1 as described in the NCBI UniGene database. (b) Alignment of the conserved segment of the human, mouse, and rat Geminin promoters. The gray box indicates the conserved E2F-binding motif (5 0 -TTTGGCGC-3 0 ). Positions of the conserved segment are numbered relative to the transcription initiation site at þ 1 E2F regulates Geminin and Cdt1 K Yoshida and I Inoue found three putative E2F-responsive sequences at positions À1183/À1176 (5 0 -TTTCGCTC-3 0 ), À24/À17 (5 0 -TTTCCCGC-3 0 ; opposite to the direction of transcription), and À16/À9 (5 0 -TTTGGCGG-3 0 ) (Figure 1c ). The presence of multiple E2F-binding motifs and GCbox sequences has been noted in other growth-regulated genes, such as E2F1 (Johnson et al., 1994) and MCM7 (Suzuki et al., 1998) (Figure 1d ). To assess the individual contribution of each of these putative elements to the basal promoter activity, first of all, we generated a human Geminin promoter-luciferase construct containing a Geminin promoter with the 5 0 end residing at position À2736 and the 3 0 end at position þ 2244 relative to the transcriptional initiation site and inserted it into a luciferase reporter construct (designated À2736/ þ 2244, hereafter called pGL3-4.98 kb) (Figure 1a ). For generating a human Cdt1 promoter-luciferase construct, a Cdt1 promoter with the 5 0 end residing at position À1197 and the 3 0 end at position þ 543 relative to the transcriptional initiation site was cloned into a luciferase reporter construct (designated À1197/ þ 543, hereafter called pGL3À1.74 kb) ( Figure 1c ). As a control promoter sequence, we used the promoter region of human MCM7 (À16/ þ 444, pGL3À0.46 kb), which has been shown to be induced by E2F (Suzuki et al., 1998) . Additionally, we cloned a 5 0 -extended MCM7 promoter (À2856/ þ 444, pGL3À3.3 kb), which contained four E2F-binding motifs (Figure 1d ). These promoter constructs were used to study transient gene expression by transfecting them into HCT116 cells and evaluating the firefly luciferase activities by measuring the chemiluminescence with a luminometer. The transfection efficiency was normalized by a dual luciferase assay, which was used to measure the corresponding Renilla luciferase activity on cotransfection of the pRL-TK plasmid.
As shown in Figure 2a , the full-length Geminin promoter construct, pGL3À4.98 kb, showed approximately 400-fold activity in human colon cancer HCT116 cells, as determined by measuring the relative luciferase activities, taking that in the control luciferase vector pGL3-basic as 1. This extraordinarily strong activity of the Geminin promoter could explain how the Geminin protein is present in rather abundant amounts in human cells (data not shown). To determine in greater detail the cis-elements essential for the basal promoter activity of Geminin, various deletion reporter constructs were generated ( Figure 1a) . Interestingly, the Geminin promoter construct, pGL3À3.0 kb, which lacked any intron 1 sequence including an E2F-binding motif, showed reduced promoter activity as compared to fulllength pGL3À4.98 kb (Figure 2a ). Further deletion of the 5 0 part of the promoter segments from pGL3À3.0 kb was not associated with any significant change of the promoter activity. pGL3À2.73 kb, obtained by deletion of the exon 1 sequences from pGL3À3.0 kb, showed a slight decrease of the promoter activity. On the other hand, pGL3À0.46 kb, which was obtained by deletion of the TATA-box sequences from pGLÀ3.0 kb, showed promoter activity almost equal to that of pGL3À3.0 kb. In contrast, pGL3À0.22 kb, obtained by deletion of exon 1 sequences from pGL3À0.46 kb, exhibited a dramatically decreased promoter activity, although the overall activity was still strong (over 50-fold activation that of pGL3-basic). In addition, pGL3À0.19 kb, not containing a segment containing an E-box sequence, and pGLÀ0.07 kb, containing a proximal Sp1 site but lacking other Sp1 sites, also exhibited basal promoter activity. This minimal promoter activity was as strong as that of the pGL3-promoter, which is driven by the SV40 promoter. These results suggest that while the proximal Sp1 sites may play critical roles in maintaining the basal human Geminin promoter activity, the E2F-binding motif is important for maximal activity of the Geminin promoter.
In the case of the human Cdt1 promoter, deletion promoter constructs were generated based on the position of the E2F-like motif ( Figure 1c) ; however, the overall promoter activity remained unchanged in all of the constructs prepared ( Figure 2b ). As suggested for the human Geminin promoter, the GC-box sequence probably plays a critical role in maintaining the basal 
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On the other hand, as characterized previously, 0.46-kb segments located within exon 1 of MCM7 also showed basal promoter activity (Suzuki et al., 1998) . The longer version of the human MCM7 promoter construct, pGL3À3.3 kb, showed almost equal activity to that of pGL3À0.46 kb (Figures 1d and 2c) .
Identification of the E2F-regulatory region of the Geminin and Cdt1 promoter
Next, we sought evidence to show that members of the E2F family transcriptionally regulate the Geminin and Cdt1 genes. As shown in Figure 3a , exogenous coexpression of E2F1-4 caused up to a twofold increase in the Geminin pGL3À4.98 kb promoter activity, whereas that of E2F5 was associated with downregulation, and that of E2F6 and E2F7 was associated with no activity as compared to that of the pcDNA3 control vector. To determine that the E2F-responsive site in the Geminin promoter is at þ 378/ þ 385, we introduced mutations at þ 378/ þ 385 of the pGL3À4.98 kb construct (designated deltaE2F; see Materials and methods). The deltaE2F construct was not stimulated by any of the E2Fs (Figure 3a ). These results indicate that the responsiveness of the Geminin promoter to E2F1-4 is dependent on the E2F-responsive sequence located at þ 378/ þ 385. To determine whether members of the E2F family also regulate endogenous Geminin mRNA expression, HCT116 cells were transfected with E2F1-7, and the isolated total RNA was subjected to real-time RT-PCR analysis. As illustrated in Figure 3b , exogenous coexpression of E2F1-4 caused up to a twofold increase in the endogenous Geminin mRNA expression, and whereas that of E2F5 was associated with slight downregulation of activity, and that of E2F6 and E2F7 was associated with the absence of activity, as compared to that of the pcDNA3 control vector. To clarify the expression level of each of the overexpressed E2F proteins, cell lysates were prepared after 48 h of transfection and Western blot analysis was performed.
As shown in Figure 3c , HA-tagged E2F1-6 and Myc- To confirm these observations further, the E6 and E7 oncogenes of HPV type 16 were cotransfected with the Geminin pGL3À4.98 kb promoter construct or the deltaE2F construct. The E7 protein is the major oncogenic protein produced by cervical cancer-associated HPV type 16 (zur Hausen, 1999) . Since the product of the E7 oncogene can bind to and downregulate pRb expression, the released E2Fs were allowed to interact with the responsive sequence of the target genes (Boyer et al., 1996; Lee et al., 1998) . As expected, the Geminin pGL3À4.98 kb promoter construct was activated by E7, but not by E6 or the pLXSN vector alone (Figure 3d ). On the other hand, the deltaE2F promoter construct failed to show any increase of activity, indicating the specificity of the þ 378/ þ 385 sequence for regulation by the pRb/E2F pathway. We further confirmed E7-dependent upregulation of endogenous Geminin mRNA by real-time RT-PCR. As shown in Figure 3e , elevation of the Geminin mRNA expression level (two-fold) in HCT116 cells was specifically detected when E7, but not E6, was overexpressed.
Similarly, to identify the critical E2F-responsive sequences, which activate the Cdt1 promoter construct, we employed various deletion mutants as indicated in Figure 1c , and examined whether or not they were activated by the E2Fs. As shown in Figure 4a , pGL3À1.74 kb, which contained three E2F-responsive sequences, was activated by E2F1-4, but not by E2F5-7 or the pcDNA3 control vector. On the other hand, the pGL3À1.71 kb promoter construct, which lacks an E2F-responsive sequence, remained fully responsive to E2F2-4. E2F1-induced activation of pGL3À1.71 kb was partially suppressed, indicating that an E2F-responsive sequence located in the 5 0 most part of pGL3À1.74 kb could be preferentially regulated by E2F1. Whereas the pGL3À0.58 kb promoter construct, which still contained two E2F-responsive sequences but lacked the À1167/À27 region where no canonical E2F-responsive sites are found, remained partially responsive to E2F1-4, the pGL3À0.55 kb promoter construct, which did not contain any E2F-responsive sequence, showed defective E2F response (Figure 4a ). These results suggest that the two overlapping E2F-responsive sequences located at À24/À9 are essential, but that another critical E2F-responsive site(s) may be present in the À1167/À27 region. Importantly, overexpression of E2F1-4, but not of E2F5 or E2F6, and pcDNA3 in HCT116 cells stimulated the expression of endogenous Cdt1 mRNA, as detected by RT-PCR (Figure 4b) .
To clarify the involvement of the pRb/E2F pathway in the regulation of human Cdt1 expression, we cotransfected cells with pRb-family proteins with E2F1/DP2 or E2F4/DP2. As shown in Figure 4c , DP2 overexpression, with or without the pRb-family proteins, did not contribute to the promoter activity of the pGL3À1.74 kb construct. On the other hand, coexpression of DP2 with E2F4, but not E2F1, synergistically 
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K Yoshida and I Inoue increased the activity of the pGL3À1.74 kb promoter construct. It is considered that DP2, which has a nuclear localization signal (NLS), enhances the binding of E2F4, which itself lacks a NLS, to target sites. DP1 and 2 are known to be abundantly present proteins in human cells, but ectopic DP2 expression may facilitate access of the E2F4 protein to the target element. Therefore, an expression plasmid of each member of the pRb family of pocket proteins, pRb, p107, and p130, together with E2F1/DP2 or E2F4/DP2, was cotransfected with the pGL3À1.74 kb promoter construct, and the luciferase activities were examined. As expected, coexpression of pRb along with E2F1/DP2 decreased the activity of the pGL3À1.74 kb promoter construct. In contrast, neither expression of p107 nor that of p130 decreased the activity of the pGL3À1.74 kb promoter construct, whereas the enhanced reporter activity induced by E2F4/DP2 was markedly inhibited by cotransfection with pRb, p107, and p130 ( Figure 4c ). These results are consistent with the current thinking that pRb interacts with E2F1-4, whereas p107 and p130 interact with E2F4, but not with E2F1-3 (Grana et al., 1998) . These observations strongly support the idea that a pRb/E2F pathway regulates the Cdt1 promoter activity. Similar to the results for the Geminin and Cdt1 promoters, the human MCM7 promoter construct was also activated by E2F1-4, but not by E2F5-7 (Figure 5a ). Interestingly, E2F5 activated the pGL3À3.3 kb, but not pGL3À0.46 kb promoter construct, suggesting that the E2FÀbinding site located at the 5 0 most part of the pGL3À3.3 kb construct has a different binding ability to the E2Fs.
Furthermore, we also assayed the contribution of the E-box sequence 5 0 -CACGTG-3 0 (À9/À4) in the activation of the Geminin promoter construct. Myc oncoprotein can bind to a core E-box promoter sequence CAC/ TGTG after forming a heterodimer with Max. The MCM7 promoter has an E-box-binding site and is a direct target of Myc (Shohet et al., 2002) . As shown in Figure 5b , c-Myc failed to activate the Geminin promoter, although it activated the MCM7 promoter.
Activation of the Geminin and Cdt1 genes by serum stimulation
To determine whether the promoter region of human Geminin and Cdt1 are growth-dependent, we assayed the activity of the promoter in serum-starved and thereafter stimulated HCT116 cells. Transfected cells were brought to quiescence by serum starvation, and then serum was added to stimulate their re-entry into the cell cycle. The cells were harvested, and their extracts were prepared, and assayed for luciferase activity. The cell cycle distribution of the HCT116 cells was followed by FACS analysis of DNA-stained cells, which revealed that the S-phase cells were present at the maximum number at B24 h after serum restimulation, with a subsequent increase in the G2/M cell population at B30 h after serum restimulation (Figure 6a) . A representative time-course experiment shown in Figure 6b demonstrates that the activities of the Geminin (pGL3À4.98 kb) and Cdt1 (pGL3À1.74 kb) promoters, as well as that of the MCM7 (pGL3À3.3 kb) promoter, were induced by release from serum starvation during the mid-to-late S-phase (24 h after serum addition) of the cell cycle, as determined by the reporter assay with the isolated fragments (3-5-fold increase of the promoter activity), indicating that the growth-dependent regulatory elements are contained within the region used for these experiments. Induction of expression of MCM7 by serum stimulation has been reported (Ohtani et al., 1999) . The E2F-responsive-site-mutated Geminin promoter construct (delta E2F) showed a decreased activity as compared with that of the wild-type E2F regulates Geminin and Cdt1 K Yoshida and I Inoue pGL3À4.98 kb promoter construct, providing strong evidence for a central role of E2F activity in the regulation of cell cycle progression, including the initiation of DNA replication mediated by Geminin. Consistent with the E2F-dependent upregulation of the Cdt1 promoter construct (Figure 4a) , we detected decreased promoter activity with pGL3À0.58 kb and À0.55 kb constructs (data not shown). The pGL3-basic control construct showed similar activity before and after serum stimulation (Figure 6b) . The time-course of changes of endogenous Geminin, Cdt1, and MCM7 mRNA expression during the cell cycle was similar to that of the expression of the respective promoters (Figure 6c ).
E2Fs bind to the Geminin and Cdt1 promoters in vivo
To substantiate the contention that E2Fs can bind to endogenous human Geminin and Cdt1 promoters, chromatin immunoprecipitation (ChIP) assays were performed using antibodies against E2F1, E2F2, and E2F4, and also c-Myc. The chromatin immunoprecipitated by the antibodies was then amplified by PCR with primers specific for Geminin, Cdt1, MCM7 or the control actin promoter (Figure 7a ). DNA fragments containing the þ 378/ þ 385 region in Geminin, and the À24/À9 region in the Cdt1 promoter were detected, whereas no genomic DNA fragment was detected when irrelevant antibody (anti-FLAG) or no added antibody was used instead of the anti-E2F antibodies, as shown in Figure 7b . The intensity of the amplified PCR fragment was clearly weaker in Geminin than in Cdt1, probably due to the presence of a tandem E2F-binding site in the promoter region of Cdt1. PCR primers specific for the human actin promoter (negative control) did not yield actin promoter DNA in any of the E2F-ChIP samples, as expected from the previous work demonstrating that ChIP assays were performed using no antibody, an irrelevant antibody (anti-FLAG), and antibodies against E2F1, E2F2, and E2F4. PCR primers for the Geminin, Cdt1, and actin promoter were used to detect promoter fragments in the immunoprecipitates. The input lane represents 0.5% of the total chromatin used in the ChIP assays. (c) c-Myc binds to MCM7, but not to the Geminin promoter, in vivo. ChIP assays were performed using no antibody, an irrelevant antibody (anti-FLAG), and antibodies against c-Myc. PCR primers for the Geminin and MCM7 promoter were used to detect promoter fragments in the immunoprecipitates. The input lane represents 0.5% of the total chromatin used in the ChIP assays 
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K Yoshida and I Inoue E2F does not bind to the actin promoter (Takahashi et al., 2000) . These results indicate that E2Fs associate with the Geminin and Cdt1 promoters under physiological conditions. On the other hand, as shown in Figure 7c , PCR primers that span the region of À196 to þ 24, including the E-box element of the Geminin promoter, failed to yield any Geminin promoter DNA in ChIP samples generated using anti-c-Myc antibody. However, chromatin immunoprecipitated by anti-c-Myc antibody subjected to PCR to detect the MCM7 promoter region spanning the E-box sequence yielded a clear PCR fragment (Figure 7c ).
Discussion
In this study, we isolated the promoter region of the human Geminin and Cdt1 genes and analysed the mechanism underlying E2F-dependent activation of these genes. In transient transfection assays, the Geminin and Cdt1 promoters were specifically activated by E2F transcription factors. Our results therefore demonstrated that Geminin and Cdt1 constitute targets of the various E2F transcription factors. Furthermore, the growth-regulated expressions of human Geminin and Cdt1 are mediated mainly via the actions of the E2F transcription factors. Previous studies have shown that the expression of E2F1 and E2F2, but not that of E2F3-5, specifically induced cyclin A, whereas expression of E2F3 preferentially induced DHFR and cdk2 (DeGregori et al., 1997). Various experimental results suggest that the individual E2F proteins might perform distinct functions in cell growth and cell fate. For instance, E2F1 has the unique ability to promote apoptosis (DeGregori et al., 1997; Kowalik et al., 1998; Moroni et al., 2001 ); on the other hand, E2F3 appears to be critically important for cellular proliferation (Humbert et al., 2000) . These findings prompted us to examine whether the E2F family of transcription factors activated Geminin and Cdt1 promoter constructs. To determine which of the E2Fs modulated the activity of the Geminin and Cdt1 promoters most potently, several members of the E2F family were tested in luciferase reporter assays. Our results clearly demonstrated that the human Geminin and Cdt1 promoters are most potently activated by the growth-promoting (E2F1-3), as well as the growth-repressing E2F transcription factors (particularly E2F4). These results suggest that Geminin and Cdt1 constitute targets of various members of the E2F family of transcription factors. E2F4 is involved mainly in the repression of gene expression; however, it is possible that this factor also activates transcription under some circumstances. For example, E2F4 has been detected on certain mouse promoters in the late G1/S phase as well as the G0 phase (Wells et al., 2000) . Moreover, ChIP assays performed on native HCT116 cells revealed that the observed regulation by the E2Fs is a physiological event. Although the expression level of the Geminin and Cdt1 mRNA in HeLa cells did not change dramatically through the various phases of the cell cycle (Nishitani et al., 2001; Kulartz et al., 2003) , both Geminin and Cdt1, as well as MCM7, were induced in HCT116 cells by release from serum starvation in the late S phase (24 h after) of the cell cycle, as determined by real-time RT-PCR and reporter assays using isolated fragments. In particular, this experiment demonstrated that an E2F repressor activity is responsible for repression of the Geminin gene; this activity is likely to be mediated by the E2F5/ p130 rather than the E2F4/p130 complex, based on the findings that this complex dominates in quiescent cells and that only E2F5 negatively regulated the Geminin promoter activity. It is somewhat surprising that Geminin and Cdt1 are activated by E2F4 but not by E2F5, even though E2F4 and E2F5 are known to be rather similar proteins. One possibility is that many E2F-responsive genes, in particular, DNA replication and DNA repair genes, are collaboratively regulated by E2F1 and E2F4 (Takahashi et al., 2000) . Another possibility is that the E2Fs are differentially associated with as yet uncharacterized transcriptional factors. Indeed, E2F2 and E2F3, but not E2F1, have been shown to exhibit a specific interaction with YY1 and its binding protein, RYBP. They have the potential to interact with their respective binding sites in the Cdc6 promoter (Schlisio et al., 2002) . It is possible in the case of Geminin and Cdt1, that the proper partner protein interacts with E2F4, but not with E2F5, to form a functional transcription complex for gene activation. Alterations in Myc and the pRb/E2F pathway are hallmarks of cancer. Deregulated c-Myc expression generates genomic instability and acts as a promoter of neoplastic transformation through the induction of certain proliferation-promoting genes, including MCM7 (Mai et al., 1996; Felsher and Bishop, 1999; Li and Dang, 1999; Shohet et al., 2002) . Although Geminin also has a core E-box element, neither c-Myc binding nor enforced promoter activity induced by overexpression of c-Myc was observed. Thus, Myc is not likely to play a significant role in the transcriptional activation of Geminin.
Timely initiation of DNA replication is strictly controlled through a process called licensing (Blow and Laskey, 1988) . In vertebrates, licensing is negatively controlled by Geminin, which is expressed from the S phase of the cell cycle through the end of mitosis. It was recently shown that Geminin formed a complex with Cdt1 in human cells, suggesting that it inhibited licensing by binding to and inactivating Cdt1, an MCMloading factor (Wohlschlegel et al., 2000) . Interestingly, although Geminin acts as an inhibitor of cellular proliferation, it is widely expressed in numerous malignancies (Wohlschlegel et al., 2002; Hansel et al., 2003) . Overexpression of Cdt1 promoted rereplication in human cells with inactive p53, indicating the importance of the Geminin/Cdt1 balance in the prevention of rereplication (Vaziri et al., 2003) . When this balance is destroyed, cancer cells may easily overcome the barriers to rereplication, and gene amplification events are initiated. Therefore, Geminin and Cdt1 overexpression may possibly be associated with neoplastic transformation. In this context, analysis of the transcriptional E2F regulates Geminin and Cdt1 K Yoshida and I Inoue regulation of Geminin and its binding partner Cdt1 could be expected to contribute to not only a clearer understanding of the mechanism of regulation of timely initiation of DNA replication, but also to determining the correlation between deregulated Geminin and Cdt1 gene activation and tumorigenesis. Disruption of the cell cycle control mechanism is one of the key features of human cancer, and E2F is the most important downstream target of pRb. In this report, we show that modulation of a pRb/E2F pathway is directly linked to regulation of the Geminin and Cdt1 promoter activity, suggesting that disruption of pRb or activation of certain members of the E2F family can lead to overexpression of Geminin and Cdt1 protein. Examination of the expression level of Geminin and Cdt1 in tumor specimens may be expected to provide a clearer insight as to how aberration of Geminin and Cdt1 might contribute to the development of various cancers.
Materials and methods
Plasmids
The human Geminin, Cdt1, and MCM7 promoter fragments were generated by PCR from genomic DNA, ligated into the pGL3-basic vector (Promega), and sequenced. Initial PCR primers were designed to amplify 4980 bp (À2736/ þ 2244), 1740 bp (À1197/ þ 543), and 3300 bp (À2856/ þ 444) of the Geminin, Cdt1, and MCM7 promoter sequences, respectively, which are numbered relative to the transcription initiation site at þ 1 described in the NCBI UniGene database (Genome View). The genomic clones (GenBank Accession number) used for the designation of PCR primers were human Geminin (NT_007592), Cdt1 (AC092384), and MCM7 (AC073842), respectively. The forward (F) and reverse (R) PCR primers for the full-length promoter constructs were, 5
, respectively. Deletion mutants of the Geminin, Cdt1, and MCM7 promoter constructs were generated using the following primers:
0 -GCCCCTTCCCAGCCC-CAAGGGTCTAGGATA-3 0 (À16F). The forward primer added a KpnI site, and the reverse primer added an XhoI (for Geminin) or HindIII (for Cdt1 and MCM7 promoter constructs) site to facilitate subcloning. The E2F-responsive sequence-mutated promoter construct À2736/ þ 2244 (designated deltaE2F) was created using primers À2736F and 5 0 -CTAGCTAGCACCGACCCAGCCAATGGGGCAGTCCC-TCGA-3 0 (NheI site), 5 0 -CTAGCTAGCGCGCTCTCACTT-CCGCGCTTCCTATTGGC-3 0 (NheI site) and þ 2244R. Thus, the 3 0 part of E2F-responsive sequence at position þ 378/ þ 385 (5 0 -TTTGGCGC-3 0 ) was replaced with NheI sequence.
The pcDNA3-HA-E2F1, E2F2, E2F3, E2F4, and E2F6 expression plasmids were gifts from Dr Joseph R Nevins (Duke University Medical Center). The pCMV-HA-E2F5, DP2, pRb, p107, and p130 expression plasmids were supplied from Dr Junji Magae (Institute of Research and Innovation, Japan). The pCMV-5xMyc-E2F5 and E2F7 expression vector was provided by Dr Gustavo Leone (The Ohio State University). The pRcCMV-pRb expression vector was a gift from Dr Robert A Weinberg (Whitehead Institute for Biomedical research, MIT). The retroviral-based expression plasmids pLXSN encoding E6 or E7 of HPV type 16 were kindly provided by Dr. Denise A. Galloway (Fred Hutchinson Cancer Research Center). The pCMV-SPORT6 c-Myc and Max plasmids were purchased from Invitrogen (I.M.A.G.E. 2985844 and 5205305, respectively).
Cell culture, synchronization, and transfections HCT116 cells were cultured in McCoy's 5A medium (Invitrogen) containing 10% (v/v) fetal bovine serum (FBS) (Invitrogen) and antibodies (penicillin and streptomycin) at 371C under 5% CO 2 . The cells were transfected with FuGENE6 (Roche) according to the manufacturer's instruction. Briefly, 200 ng of expression plasmid, 200 ng of firefly luciferase reporter plasmid (pGL3, Promega), and 0.6 ng of Renilla luciferase reporter plasmid (pRL-TK, Promega) per 24-well dish were used in each transfection. The cells were harvested 48 h after transfection, and luciferase assay was performed using the Dual-Luciferase Reporter Assay System following the manufacturer's protocol (Promega). Experiments were done at least in triplicate, and the relative activities and s.e. values were determined. To control for transfection efficiency, firefly luciferase values were normalized to the values for Renilla luciferase.
To measure growth-dependent induction of the human Geminin, Cdt1, and MCM7 promoter activities, transfected HCT116 cells were arrested in the G0 phase by incubation in the presence of 0.1% FBS for 48 h, and then released into the cell cycle by readdition of 15% FBS. The cells were harvested at 0, 16, 24, and 30 h after serum stimulation and were assayed for luciferase activity. The cell cycle distribution was assessed with a FACScan flow cytometer (Becton Dickinson) with Cell Quest software.
RT-PCR
Total RNA was prepared using the TRIZOL reagent (Invitrogen) according to the manufacturer's instructions. The reverse transcription reaction was carried out using SuperScript II reverse transcriptase from Invitrogen, following the recommendations of the manufacturer. The PCR settings were as follows: 1 min at 941C, 1 min at 551C, and 1 min at 721C for 28 cycles. The primer sequences for the amplification of Geminin and Cdt1 mRNA are 5 0 -CATCTACAACTTC-CAGCCCTGGGGTTA-3 0 and 5 0 -GAACTAGTGGAGG-TAAACTTCGGCAGT-3 0 , 5 0 -TGGGCACCTGTCGTCCC-AGC-TACTAGGGAG-3 0 and 5 0 -TTCAAAGCTGGCTGG-CTCTGGCCCTGTCAT-3 0 , respectively. Amplified products were separated through 1.2% agarose gels and visualized on an ultraviolet transilluminator. Also, quantitative RT-PCR was performed using indicated primers with SYBR green (PE Biosystems) on the ABI Prism 7700 sequence detection system. Final reaction products were run on a 1.2% agarose gel and confirmed to be a single band at the correct molecular weight. Geminin and Cdt1 mRNA were normalized to GAPDH mRNA levels.
Western blot analysis
The cells were harvested and lysed in RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP40, 0.5%. sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 1 mM NaF and 1 mg/ml each of aprotinin, pepstatin and leupeptin) for 20 min on ice. The cell lysates were centrifuged and protein concentration was determined by Bio-Rad protein assay kit (Bio-Rad laboratories). Before being subjected to SDS-PAGE, the reaction was stopped by adding Laemmli sample buffer containing 100 mM DTT. Equal amounts of cellular protein (25 mg) were electrophoresed in NuPAGE 4-12% Bis-Tris gel with MES running buffer (Invitrogen) and transferred to a Hybond-PVDF membrane (Amersham). The membrane was first blocked in TBS containing 0.1% Tween 20 and 5% non-fat dried milk and then incubated with the following antibodies: mouse anti-myc-HRP (Invitrogen) or mouse anti-HA-HRP (Santa Cruz Biotechnology). Enhanced chemiluminescence reagents were used to detect the signals according to the manufacturer's protocol (ECL Plus, Amersham).
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as previously described (Dhar et al., 2001) . Briefly, a subconfluent 150 cm 2 dish of HCT116 cells were used for each ChIP, and asynchronously growing cells were treated with formaldehyde to 1% final concentration to create protein-DNA cross-links, and the cross-linked chromatins were then extracted, diluted with RIPA buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, and protease inhibitor cocktails), and sheared by sonication on ice to an average length of 700 bp. After precleared with the protein Asepharose beads (41C for 4 h), blocked with 1% bovine serum albumin, the chromatin was divided into equal samples for immunoprecipitation together with 2-5 mg of either anti-E2F1 (sc-193), anti-E2F2 (sc-633), anti-E2F4 (sc-866), anti-c-Myc (sc764) polyclonal antibodies (Santa Cruz Biotechnology), and anti-FLAG monoclonal antibody (Sigma) or no antibody. After 41C overnight, 15 ml aliquot of 50% slurry of pre-blocked protein A-sepharose beads was added and immune complexes were pelleted by centrifugation after 3 h incubation at 41C, and washed several times with RIPA buffer. Immunoprecipitates were resuspended in TE buffer and cross-links reversed at 651C with proteinase K and RNase A overnight. Following phenol/ chloroform extraction and ethanol precipitation, pellets were resuspended in 50 ml of distilled water and analysed by PCR. For input control, 1/200 volume of chromatin was amplified. PCR primers (Geminin E2F, 5 0 -CGCACAGCCTCTAGAC-GACTCGCTTTCCCT-3 0 and 5 0 -GCCTCGGGAACTGC-GCCAGCCAGCCAATAG-3 0 ; Cdt1 E2F, 5 0 -AGACCGC-GCTAAAGTCCCACGCACGACGGC-3 0 and 5 0 -AAGA-AGTCGGTGACGCGGCGCTGCTCCATG-3 0 ; Geminin Ebox, À196F and þ 24R; MCM7 E-box, À16F and þ 444R) that generate 230, 290, 220, and 460 bp products, respectively, were used to detect the presence of specific DNA sequences. PCR primers corresponding to the human actin promoter (negative control) were previously described (Takahashi et al., 2000) .
Abbreviations DHFR, dihydrofolate reductase; pRb, retinoblastoma protein; MCM, minichromosome maintenance; HPV, human papillomavirus; FBS, fetal bovine serum; ChIP, chromatin immunoprecipitation; HDAC, histone deacetylase.
